This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Matias K, Matias C, Teixeira H, Freire AD, Azevedo A . Successful pregnancy following busulfan and cyclophosphamide conditioning and allogeneic bone marrow transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2008; 14: 944–945.
Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385.
Nakagawa K, Kanda Y, Yamashita H, Hosoi Y, Oshima K, Ohtomo K et al. Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation: a report of two successful cases. Bone Marrow Transplant 2006; 37: 583–587.
Nakagawa K, Kanda Y, Yamashita H, Nakagawa S, Sasano N, Ohtomo K et al. Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic stem cell transplantation recipients undergoing total body irradiation. Bone Marrow Transplant (in press); e-pub ahead of print 11 August 2008, PMID 18695667.
Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128–135.
Hartman AR, Williams SF, Dillon JJ . Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439–443.
Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569–3574.
Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia nordic bone marrow transplantation group. Blood 1999; 93: 2196–2201.
Kanda Y, Sakamaki H, Sao H, Okamoto S, Kodera Y, Tanosaki R et al. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant 2005; 11: 881–889.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Okuda, S., Sato, M., Terasako, K. et al. Should busulfan-containing regimen be avoided for young female patients undergoing hematopoietic stem cell transplantation?. Bone Marrow Transplant 43, 261–262 (2009). https://doi.org/10.1038/bmt.2008.309
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.309
This article is cited by
-
Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation
Annals of Hematology (2014)
-
Risks and benefits of ovarian shielding in female patients undergoing TBI: a decision analysis
Bone Marrow Transplantation (2011)